Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poterepatide (HDM1005) in T2DM with Inadequate Glycemic Control
NCT07109700Phase 2Recruiting
- Sponsor
- Huadong Medicine
- Start
- Apr 2025
- Primary completion
- Jan 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of poterepatide in type 2 diabetes mellitus (T2DM), sponsored by Huadong Medicine. Started Apr 2025; status: recruiting.
02
Drugs
poterepatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07109700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07109700.